- Mizuho analyst Vijay Rakesh reiterated a Buy on Broadcom Inc (NASDAQ:AVGO) and a $725 price target reflecting technology leadership with Tomahawk 4/5, growing Software, industry-leading margins, and FCF.
- Mizuho hosted AVGO’s CEO Hock Tan, CFO Kirsten Spears, and IR Ji Yoo.
- Rakesh noted strong demand with a continued leading market position. Broadcom’s overall customer lead times remained at ~50 weeks, and its manufacturing lead times potentially improved.
- Broadcom’s gross margin improvement came from better uptake/adoption/mix from more robust adoption of newer next-gen products.
- Broadcom’s goal is to become the “golden screw” for customers’ match-sets, shipping to ‘true’ end-demand.
- Broadcom is committed to investing in VMWare’s core competency following the acquisition as it looks to build its software business.
- Price Action: AVGO shares traded higher by 2.36% at $524.13 on the last check Friday.
Gilead’s Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of “Risks Of Secondary Cancer’
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list.
